Expertise in
16
conditions

Dr. Kellie A. Sprague

Hematology | Hematology Oncology
265 Western Ave, Suite 2, 
South Portland, ME 
Offers Telehealth
31 Years of Experience
Expertise in
16
conditions
265 Western Ave, Suite 2, 
South Portland, ME 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Kellie Sprague is a Hematologist and a Hematologist Oncology provider in South Portland, Maine. Dr. Sprague has been practicing medicine for over 31 years is highly rated in 16 conditions, according to our data. Her top areas of expertise are Acute Promyelocytic Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), Bone Marrow Aspiration, and Bone Marrow Transplant.

Her clinical research consists of co-authoring 10 peer reviewed articles and participating in 8 clinical trials. MediFind looks at clinical research from the past 15 years.

Specialties
Hematology
Hematology Oncology
Licenses
Internal Medicine in MA
Hospital Affiliations
Mainehealth Stephens Hospital
Mainehealth Maine Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
Change Healthcare
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Cigna
  • EPO
  • HMO
  • PPO
Community Health Options
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Martin's Point Generations
  • MEDICARE MAPD
  • OTHER MEDICARE
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Simply Healthcare
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • OTHER MEDICARE PART D
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 7 Less Insurance Carriers -

Locations

MAINEHEALTH
265 Western Ave, Suite 2, South Portland, ME 04106
Other Locations
MAINEHEALTH
22 Bramhall St, Portland, ME 04102

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

8 Clinical Trials

Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Randomized Trial of Gilteritinib vs Midostaurin in FLT3 Mutated Acute Myeloid Leukemia (AML)
Enrollment Status: Active_not_recruiting
Publish Date: June 15, 2025
Intervention Type: Drug
Study Drugs: Gilteritinib, Midostaurin, Daunorubicin, Cytarabine
Study Phase: Phase 2
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
GRAVITAS-309: A Phase 2/3 Study of Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease
Enrollment Status: Terminated
Publish Date: January 27, 2025
Intervention Type: Drug
Study Drugs: Itacitinib, Methylprednisolone, Prednisone
Study Phase: Phase 2/Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin &Amp; Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnosed Acute Myeloid Leukemia in Older Adults (Age >/= 60 Years)
Enrollment Status: Completed
Publish Date: December 13, 2024
Intervention Type: Drug, Other, Procedure
Study Drugs: Clofarabine, Daunorubicin, Cytarabine, Decitabine
Study Phase: Phase 3
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
A Phase III, International, Randomized, Controlled Study of Rigosertib Versus Physician's Choice of Treatment in Patients With Myelodysplastic Syndrome After Failure of a Hypomethylating Agent
Enrollment Status: Terminated
Publish Date: September 26, 2022
Intervention Type: Drug
Study Drug: Rigosertib
Study Phase: Phase 3
A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
A Phase I Trial of Venetoclax (ABT-199) and Dexamethasone for Relapsed or Refractory Systemic AL Amyloidosis
Enrollment Status: Terminated
Publish Date: August 21, 2020
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
An Open-label, Multi-center, Expanded Treatment Protocol of Midostaurin (PKC412) in Adult Patients With Newly Diagnosed Fms-like Tyrosine Kinase Receptor (FLT3) Mutated Acute Myeloid Leukemia (AML) Who Are Eligible for Standard Induction and Consolidation Chemotherapy.
Enrollment Status: No_longer_available
Publish Date: July 15, 2020
Intervention Type: Drug
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
A Randomized, Double-blind Phase 3 Study of Vadastuximab Talirine (SGN-CD33A) Versus Placebo in Combination With Azacitidine or Decitabine in the Treatment of Older Patients With Newly Diagnosed Acute Myeloid Leukemia (AML)
Enrollment Status: Terminated
Publish Date: December 12, 2018
Intervention Type: Drug
Study Phase: Phase 3
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
A Children's Oncology Group Protocol for Collecting and Banking Pediatric Research Specimens Including Rare Pediatric Tumors
Enrollment Status: Completed
Publish Date: July 19, 2018
Intervention Type: Other
View 7 Less Clinical Trials

10 Total Publications

Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902.
Incorporation of extracorporeal photopheresis into a reduced intensity conditioning regimen in myelodysplastic syndrome and aggressive lymphoma: results from ECOG 1402 and 1902.
Journal: Transfusion
Published: January 03, 2020
Similar Doctors
Expertise in
17
conditions
Dr. Christopher G. Tretter
Hematology Oncology | Hematology | Oncology
Expertise in
17
conditions
Dr. Christopher G. Tretter
Hematology Oncology | Hematology | Oncology

Mainehealth

265 Western Ave, Suite 2, 
South Portland, ME 
 (0.1 miles away)
207-396-7606
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Christopher Tretter is a Hematologist Oncology specialist and a Hematologist in South Portland, Maine. Dr. Tretter is highly rated in 17 conditions, according to our data. His top areas of expertise are Prostate Cancer, Familial Prostate Cancer, Renal Cell Carcinoma (RCC), and Chromophobe Renal Cell Carcinoma. Dr. Tretter is currently accepting new patients.

Expertise in
14
conditions
Dr. Archana M. Agarwal
Hematology Oncology | Hospital Medicine | Hematology
Expertise in
14
conditions
Dr. Archana M. Agarwal
Hematology Oncology | Hospital Medicine | Hematology

Core Physicians LLC

5 Alumni Dr, 
Exeter, NH 
 (54.8 miles away)
603-580-6457
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Archana Agarwal is a Hematologist Oncology specialist and a Hospital Medicine provider in Exeter, New Hampshire. Dr. Agarwal is highly rated in 14 conditions, according to our data. Her top areas of expertise are Hereditary Pyropoikilocytosis, Hereditary Spherocytosis, Hereditary Elliptocytosis, Hereditary Ovalocytosis, and Splenectomy. Dr. Agarwal is currently accepting new patients.

Expertise in
42
conditions
Dr. Christian A. Thomas
Hematology Oncology | Hematology | Oncology
Expertise in
42
conditions
Dr. Christian A. Thomas
Hematology Oncology | Hematology | Oncology

Maine Center For Cancer Medicine And Blood Disorders PA

155 Borthwick Ave, Suite C, 
Portsmouth, NH 
 (46.3 miles away)
603-828-0100
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Christian Thomas is a Hematologist Oncology specialist and a Hematologist in Portsmouth, New Hampshire. Dr. Thomas is highly rated in 42 conditions, according to our data. His top areas of expertise are Prostate Cancer, Upper Tract Urothelial Carcinoma (UTUC), Familial Prostate Cancer, Lung Cancer, and Nephrectomy.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Sprague's expertise for a condition
ConditionClose
    View All 14 Advanced Conditions
    View All 61 Experienced Conditions
    Want to save this doctor for later?
    Sign Up
    Is this your doctor?
    Find A Second Opinion
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile